Palmitoylethanolamide - CAS 544-31-0
Catalog number: B0084-026567
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H37NO2
Molecular Weight:
299.5
COA:
Inquire
Targets:
Cannabinoid Receptor
Description:
Palmitoylethanolamide is an endogenous cannabinoid found in brain, liver, and other mammalian tissues. It is a weak ligand of the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors, and a selective GPR55 agonist (EC50 values are 4, 19 800 and > 30 000 nM at GPR55, CB2 and CB1 receptors respectively).
Nutritional supplement in health care products.
Synonyms:
N-(2-Hydroxyethyl)hexadecanamide; Palmidrol; PEA
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
Application:
Ingredient of health care products.
InChIKey:
HXYVTAGFYLMHSO-UHFFFAOYSA-N
InChI:
InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
Canonical SMILES:
CCCCCCCCCCCCCCCC(=O)NCCO
1.Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells.
Berdyshev EV;Boichot E;Germain N;Allain N;Anger JP;Lagente V Eur J Pharmacol. 1997 Jul 9;330(2-3):231-40.
The effects of arachidonic acid ethanolamide (anandamide), palmitoylethanolamide and delta9-tetrahydrocannabinol on the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-4, interleukin-6, interleukin-8, interleukin-10, interferon-gamma, p55 and p75 TNF-alpha soluble receptors by stimulated human peripheral blood mononuclear cells as well as [3H]arachidonic acid release by non-stimulated and N-formyl-Met-Leu-Phe (fMLP)-stimulated human monocytes were investigated. Anandamide was shown to diminish interleukin-6 and interleukin-8 production at low nanomolar concentrations (3-30 nM) but inhibited the production of TNF-alpha, interferon-gamma, interleukin-4 and p75 TNF-alpha soluble receptors at higher concentrations (0.3-3 microM). Palmitoylethanolamide inhibited interleukin-4, interleukin-6, interleukin-8 synthesis and the production of p75 TNF-alpha soluble receptors at concentrations similar to those of anandamide but failed to influence TNF-alpha and interferon-gamma production. The effect of both compounds on interleukin-6 and interleukin-8 production disappeared with an increase in the concentration used. Neither anandamide nor palmitoylethanolamide influenced interleukin-10 synthesis.
2.Quantification of anandamide, oleoylethanolamide and palmitoylethanolamide in rodent brain tissue using high performance liquid chromatography-electrospray mass spectroscopy.
Liput DJ;Tsakalozou E;Hammell DC;Paudel KS;Nixon K;Stinchcomb AL J Pharm Anal. 2014 Aug;4(4):234-241.
Reported concentrations for endocannabinoids and related lipids in biological tissues can vary greatly; therefore, methods used to quantify these compounds need to be validated. This report describes a method to quantify anandamide (AEA), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) from rodent brain tissue. Analytes were extracted using acetonitrile without further sample clean up, resolved on a C18 reverse-phase column using a gradient mobile phase and detected using electrospray ionization in positive selected ion monitoring mode on a single quadrupole mass spectrometer. The method produced high recovery rates for AEA, OEA and PEA, ranging from 98.1% to 106.2%, 98.5% to 102.2% and 85.4% to 89.5%, respectively. The method resulted in adequate sensitivity with a lower limit of quantification for AEA, OEA and PEA of 1.4 ng/mL, 0.6 ng/mL and 0.5 ng/mL, respectively. The method was reproducible as intraday and interday accuracies and precisions were under 15%. This method was suitable for quantifying AEA, OEA and PEA from rat brain following pharmacological inhibition of fatty acid amide hydrolase.
3.Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats.
Endocannabinoid Research Group;De Filippis D;D'Amico A;Cipriano M;Petrosino S;Orlando P;Di Marzo V;Iuvone T Pharmacol Res. 2010 Apr;61(4):321-8. doi: 10.1016/j.phrs.2009.11.005. Epub 2009 Nov 17.
The endocannabinoids anandamide and 2-arachidonoylglycerol, and the anandamide-congener, palmitoylethanolamide, are all substrates for the enzyme fatty acid amide hydrolase, and are endowed with anti-inflammatory actions exerted via cannabinoid receptors or, in the case of palmitoylethanolamide, also via other targets. We investigated the role of the endocannabinoid system during granuloma formation, a model of chronic inflammation sustained by neoangiogenesis, in rats. Granuloma was induced by subcutaneous lambda-carrageenin-soaked sponge implants on the back of male Wistar rats. After 96h, granulomas were detached and tissue formation was evaluated as wet weight; the endocannabinoid system was evaluated by the measurement of endocannabinoid levels, by LC-MS, and of cannabinoid receptor expression, by western blot analysis. Moreover, angiogenesis was evaluated by the measurement of both hemoglobin content and CD31 protein expression. Arachidonoylserotonin (AA-5-HT, 12.5-50mug/ml), an inhibitor of FAAH, and palmitoylethanolamide (PEA, 200-800mug/ml) were given locally only once at the time of implantation. Granuloma formation was accompanied by a significant decrease in endocannabinoid and palmitoylethanolamide levels paralleled by increased levels of the fatty acid amide hydrolase, responsible for their breakdown.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cannabinoid Receptor Products


CAS 614726-85-1 AM 4113

AM 4113
(CAS: 614726-85-1)

AM4113 has been found to be a CB1 antagonist and could be used in studies of some neuronal dendritic abnormalities diseases.

CAS 851728-60-4 PF 514273

PF 514273
(CAS: 851728-60-4)

PF 514273 is a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. The Ki for binding to CB1 and CB2 receptors is 1 nM ...

CAS 390824-20-1 UCM 707

UCM 707
(CAS: 390824-20-1)

UCM 707 is a potent endocannabinoid transport inhibitor (IC50 = 0.8 and 30 μM for inhibition of the anandamide transporter and FAAH, respectively). UCM 707 pote...

CAS 502486-89-7 NIDA 41020

NIDA 41020
(CAS: 502486-89-7)

NIDA-41020 is a CB1 cannabinoid receptor antagonist with Ki value of 4.1 nM.

CAS 544-31-0 Palmitoylethanolamide

Palmitoylethanolamide
(CAS: 544-31-0)

Palmitoylethanolamide is an endogenous cannabinoid found in brain, liver, and other mammalian tissues. It is a weak ligand of the cannabinoid 1 (CB1) and cannab...

CAS 180002-83-9 L-768242

L-768242
(CAS: 180002-83-9)

L-768242, an indole derivative, has been found to be a CB2 receptor agonist and was once studied to exhibit anti-nociceptive and antihyperalgesic activities in ...

CAS 686344-29-6 Otenabant (CP-945,598)

Otenabant (CP-945,598)
(CAS: 686344-29-6)

Otenabant, also known as CP-945,598, is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesi...

CAS 168273-06-1 Rimonabant

Rimonabant
(CAS: 168273-06-1)

Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.

Chemical Structure

CAS 544-31-0 Palmitoylethanolamide

Quick Inquiry

Verification code

Featured Items